Featuring a slide presentation and related discussion from Dr Michael Wang, including the following topics:
- Overview of Bruton tyrosine kinase (BTK) inhibitors and clinical data establishing the efficacy of these agents for mantle cell lymphoma (MCL) (0:00)
- Clinical investigation of ibrutinib in the front-line setting; results from the Phase III SHINE trial and voluntary market withdrawal of ibrutinib for MCL (4:36)
- Phase III TRIANGLE trial of ibrutinib combined with chemotherapy as upfront therapy for younger patients with MCL; role of autologous stem cell transplant (11:14)
- Acalabrutinib and zanubrutinib for the treatment of relapsed/refractory (R/R) MCL (14:16)
- Key findings from the BRUIN trial leading to the FDA approval of pirtobrutinib for R/R MCL (16:23)
CME information and select publications
Research To Practice | Oncology Videos